DelveInsight’s ‘Lambert–Eaton Myasthenic Syndrome (LEMS) – Epidemiology Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology of LEMS in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2028
Lambert–Eaton Myasthenic Syndrome (LEMS) - Disease Understanding
The DelveInsight Lambert–Eaton Myasthenic Syndrome (LEMS) epidemiology report gives a thorough understanding of the Lambert–Eaton Myasthenic Syndrome (LEMS) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
Lambert–Eaton Myasthenic Syndrome (LEMS)
According to the Muscular Dystrophy Association, Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disease in which the immune system attacks the body's own tissues. The attack occurs at the connection between nerve and muscle (the neuromuscular junction) and interferes with the ability of nerve cells to send signals to muscle cells. Specifically, the immune system attacks the calcium channels on nerve endings that are required to trigger the release of chemicals (acetylcholine). With fewer calcium channels, the nerve ending releases less acetylcholine. Acetylcholine is a chemical messenger that triggers muscle contraction. In people with LEMS, the lowered levels of acetylcholine are not sufficient to cause normal muscle contractions, causing muscle weakness. The disease is named for Edward Lambert and Lee Eaton, neurologists at the Mayo Clinic in Rochester, Minn., who first described the myasthenic syndrome in the 1950s and 1960s.
The Lambert–Eaton Myasthenic Syndrome (LEMS) epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Lambert–Eaton Myasthenic Syndrome (LEMS) in 7MM, Total Diagnosed Prevalence of LEMS in 7MM, Gender-specific Diagnosed Prevalence of LEMS, Type-specific Diagnosed Prevalence of LEMS, and Diagnosed Prevalence of LEMS by malignancy) scenario of Lambert–Eaton Myasthenic Syndrome (LEMS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to DelveInsight, the total number of diagnosed prevalent population of Lambert–Eaton Myasthenic Syndrome (LEMS) was found to be 3,349, in 7MM in the year 2017.
Based on the etiology, Lambert Eaton Myasthenic Syndrome (LEMS) is divided into two types; Paraneoplastic and Idiopathic. There were total 1,978 diagnosed prevalent cases of LEMS in the United States in 2017, out of which 1,154 accounted for Paraneoplastic and 824 cases accounted for Idiopathic. These cases are expected to increase and reach up to 1,441 and 1,029 cases respectively, by 2028.
As per DelveInsight assessments, in the 7MM, the majority of cases of Lambert Eaton Myasthenic Syndrome (LEMS) are Paraneoplastic form as compared to Idiopathic form. Among the two forms of Lambert-Eaton myasthenic syndrome i.e. paraneoplastic and idiopathic, the paraneoplastic form, constitutes more than a half of the cases and is mostly associated with intrathoracic neoplasms. Most of the cases in patients were seen with Small Cell Lung Cancer (SCLC); other subtypes of lung cancer are extremely rare.
Among the EU-5 countries, Germany witnessed the highest prevalent population accounting for 6.93% of the total prevalent cases in 7MM, followed by France and the United Kingdom. On the other hand, Spain witnessed the lowest number of prevalent cases in 2017.
• The report covers a descriptive overview of the Lambert Eaton Myasthenic Syndrome (LEMS), explaining its causes, risk factors, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the epidemiology of Lambert Eaton Myasthenic Syndrome (LEMS) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• Assesses growth opportunities in the 7MM countries with respect to the patient population.
• 10 Year Forecast
• 7MM countries
• Total Patient Pool with Lambert Eaton Myasthenic Syndrome (LEMS) by types
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by types
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook